Ge Healthcare Limited

General Electric Company

Affibody Ab

Imperial Innovations Limited

Peter Brian Iveson

Rajiv Bhalla

Rong Zhang

Faisal Ahmed Syud

Elin Gunneriusson

Lars B Abrahmsen

Joachim Feldwisch

Christofer Lendel

Fredrik Frejd

Brian Duh-Lan Lee

Nina Herne

Paul Schaffer

Tove Simonsson

Bard Indrevoll

Ben Newton

Magne Solbakken

Matthias Eberhard Glaser

Edvin Wilhelm Johannesen

Eric Ofori Aboagye

Mette Husbyn

Anthony Wilson

Tove Eriksson

Gareth Simon Getvoldsen

Jane Brown

Bård Indrevoll

Quang-De Nguyen

Duncan Hiscock

Salah Chettibi

Maciej Kaliszczak

Giampaolo Tomasi

Bard Indrevall

Duncan Robert R Hiscock

Susan Hoppmann

Sebastian Trousil

Daniel Kramer

Gareth Getvoldsen

Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.

HER2 binders

Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.

A method of use of an isolated polypeptide conjugated with a radionuclide, wherein the isolated polypeptide binds specifically to HER2, or a variant thereof is described. The method is for monitoring the response to HSP90 inhibition and comprises the use of the isolated polypeptide conjugated with 18F. The application also describes the use of an isolated polypeptide conjugated with 18F, wherein the isolated polypeptide binds specifically to HER2 or variants thereof, as an imaging agent to monitor uptake thereof to measure HSP90 inhibition.

HER2 polypeptides useful for imaging and monitoring tumors and cancers

The present invention relates to imaging agent compositions comprising radiolabelled c-Met binding peptides suitable for positron emission tomography (PET) imaging in vivo. The c-Met binding peptides are labelled with the radioisotopeF. Also disclosed are pharmaceutical compositions, methods of preparation of the agents and compositions, plus methods of in vivo imaging using the compositions, especially for use in the management of cancer.

Peptide radiotracer compositions

The present invention relates to technetium imaging agents comprising radiolabeled c-Met binding peptides suitable for SPECT or PET imaging in vivo. The c-Met binding peptides are labelled via chelator conjugates. Also disclosed are pharmaceutical compositions, methods of preparation of the agents and compositions, plus methods of in vivo imaging using the compositions, especially for use in the diagnosis of cancer.

Technetium labelled peptides

HER2 binding peptides labeled with aluminium-[18] fluoride complexed by NOTA

The present invention provides a novel imaging agent suitable for the non-invasive visualization of fibrosis. A precursor for the preparation of the imaging agent is also provided by the invention, as well as a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical composition. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition which comprises fibrosis is provided.

Imaging agents

Growing community of inventors

Amersham, United Kingdom

Peter Brian Iveson